Thus, we identify TPC2 as a central regulator of tumour progression and immune evasion, offering a promising therapeutic target to simultaneously impair cancer proliferation, overcome chemoresistance, and boost anti-tumour immunity particularly in HCC. This evidence concerns the gene TPCN2 and neoplasm.